Saltar al contenido
Merck

Z-004

Zaleplon solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño


Acerca de este artículo

Fórmula empírica (notación de Hill):
C17H15N5O
Número CAS:
Peso molecular:
305.33
NACRES:
NA.24
UNSPSC Code:
41116107
EC Number:
200-659-6
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

Nombre del producto

Zaleplon solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

InChI key

HUNXMJYCHXQEGX-UHFFFAOYSA-N

InChI

1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3

SMILES string

CCN(C(C)=O)c1cccc(c1)-c2ccnc3c(cnn23)C#N

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

Quality Level

Gene Information

General description

Zaleplon is a nonbenzodiazepine “Z-drug” prescribed under the trade names Sonata® or Starnoc for the treatment of insomnia. Zaleplon is often abused illicitly for its mind-altering effects. This Certified Spiking Solution® is applicable to use in LC/MS or GC/MS applications for urine drug testing, clinical toxicology, and forensic analysis.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Sonata is a registered trademark of King Pharmaceuticals Research and Development, Inc.

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes

Clase de almacenamiento

3 - Flammable liquids

wgk

WGK 1

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Monique A J Mets et al.
Sleep medicine reviews, 14(4), 259-267 (2010-02-23)
Disturbed body balance and standing steadiness are problematic for those who wake up at night or in the morning after using hypnotic drugs. As a result, falls and hip fractures are frequently reported in patients using sleep medication. A literature
Charles B Schaffer et al.
Journal of affective disorders, 128(3), 305-308 (2010-08-13)
Insomnia in patients with bipolar disorder (BD) can cause distress, daytime dysfunction, cognitive impairment, worsening of hypomanic/manic symptoms and increased suicide risk. Physicians often prescribe hypnotics for BD patients with insomnia although no hypnotic has a specific FDA indication for
Jasna Jablan et al.
Journal of pharmaceutical and biomedical analysis, 71, 35-44 (2012-08-18)
The aim of this work was to investigate the potential synergistic effect of water-soluble polymers (hypromellose, HPMC and polyvinylpyrrolidone, PVP) on zaleplon (ZAL) complexation with parent β-cyclodextrin (βCD) and its randomly methylated derivative (RAMEB) in solution and in solid state.
Adam R Lancaster et al.
Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001), 21(6), 658-665 (2012-02-10)
To summarize the signalment, clinical signs observed, time to onset of clinical signs, duration of clinical signs, and the outcome in a large case series of nonbenzodiazepine sleep aid ingestions in dogs, including 2 sleep aids that have not been
Insomnia: evidence-based approaches to assessment and management.
Kevin Morgan et al.
Clinical medicine (London, England), 11(3), 278-281 (2011-09-10)

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico